Company Filing History:
2 out of 3,540 
2 out of 975 
2 out of 89 
Years Active: 2018-2021
Title: Georg Lenz: Innovator in Cancer Prognostics
Introduction
Georg Lenz is a notable inventor based in Berlin, Germany. He has made significant contributions to the field of cancer research, particularly in developing predictive tools for patient outcomes. With a total of two patents to his name, Lenz's work focuses on improving the prognosis for patients suffering from diffuse large B cell lymphoma (DLBCL).
Latest Patents
Lenz's latest patents include a survival predictor for diffuse large B cell lymphoma. This invention provides methods and materials related to a gene expression-based survival predictor for DLBCL patients. The innovative approach aims to enhance the accuracy of survival predictions, thereby aiding in better treatment decisions for patients.
Career Highlights
Throughout his career, Georg Lenz has worked with prestigious organizations such as the National Institutes of Health, a component of the US Department of Health & Human Services, and the University of Arizona. His experience in these institutions has allowed him to collaborate with leading experts in the field and contribute to groundbreaking research.
Collaborations
Some of Lenz's notable coworkers include Andrew T Lister and Erlend B Smeland. Their collaborative efforts have further advanced the research and development of cancer prognostic tools.
Conclusion
Georg Lenz's innovative work in cancer prognostics exemplifies the impact of research and invention in improving patient outcomes. His contributions continue to influence the field of oncology and provide hope for better survival predictions for DLBCL patients.